Pancreatic cancer and immunotherapy: a clinical overview
FEF Timmer, B Geboers, S Nieuwenhuizen, M Dijkstra… - Cancers, 2021 - mdpi.com
Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a
dismal prognosis. While immunotherapy has been deemed a breakthrough treatment for …
dismal prognosis. While immunotherapy has been deemed a breakthrough treatment for …
The role of immunotherapy in pancreatic cancer
R Mukherji, D Debnath, ML Hartley, MS Noel - Current Oncology, 2022 - mdpi.com
Pancreatic adenocarcinoma remains one of the most lethal cancers globally, with a
significant need for improved therapeutic options. While the recent breakthroughs of …
significant need for improved therapeutic options. While the recent breakthroughs of …
Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
Immunotherapy approaches for pancreatic ductal adenocarcinoma (PDAC) have met with
limited success. It has been postulated that a low mutation load may lead to a paucity of T …
limited success. It has been postulated that a low mutation load may lead to a paucity of T …
Strategies for increasing pancreatic tumor immunogenicity
BA Johnson III, M Yarchoan, V Lee, DA Laheru… - Clinical Cancer …, 2017 - AACR
Immunotherapy has changed the standard of care for multiple deadly cancers, including
lung, head and neck, gastric, and some colorectal cancers. However, single-agent …
lung, head and neck, gastric, and some colorectal cancers. However, single-agent …
Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective
Y Li, S Xiang, W Pan, J Wang, H Zhan, S Liu - Frontiers in Oncology, 2023 - frontiersin.org
Pancreatic cancer is one of the most malignant tumors with increased incidence rate. The
effect of surgery combined with chemoradiotherapy on survival of patients is unsatisfactory …
effect of surgery combined with chemoradiotherapy on survival of patients is unsatisfactory …
Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions
Pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC), presents a
challenging landscape due to its complex nature and the highly immunosuppressive tumor …
challenging landscape due to its complex nature and the highly immunosuppressive tumor …
Trial watch: Dendritic cell-based interventions for cancer therapy
Dendritic cells (DCs) occupy a central position in the immune system, orchestrating a wide
repertoire of responses that span from the development of self-tolerance to the elicitation of …
repertoire of responses that span from the development of self-tolerance to the elicitation of …
Emerging trends in the immunotherapy of pancreatic cancer
Pancreatic cancer (PC) is the fourth leading cause of cancer-related deaths in the US,
claiming approximately 43,000 lives every year. Much like other solid tumors, PC evades the …
claiming approximately 43,000 lives every year. Much like other solid tumors, PC evades the …
A phase Ib study of the combination of personalized autologous dendritic cell vaccine, aspirin, and standard of care adjuvant chemotherapy followed by nivolumab for …
Despite the promising therapeutic effects of immune checkpoint blockade (ICB), most
patients with solid tumors treated with anti-PD-1/PD-L1 monotherapy do not achieve …
patients with solid tumors treated with anti-PD-1/PD-L1 monotherapy do not achieve …
The clinical terrain of immunotherapies in heterogeneous pancreatic cancer: Unravelling challenges and opportunities
M Herpels, J Ishihara… - The Journal of …, 2023 - Wiley Online Library
Pancreatic ductal adenocarcinoma (PDAC) is the most common and aggressive type of
pancreatic cancer and has abysmal survival rates. In the past two decades …
pancreatic cancer and has abysmal survival rates. In the past two decades …